{"id":722,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"retatrutide-phase-2-obesity-trial-338-adults-48-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/es\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","title":{"rendered":"Ensayo de obesidad Retatrutide fase 2: adultos 338 durante semanas 48"},"content":{"rendered":"<h2>Por qu\u00e9 este estudio se cita con frecuencia<\/h2>\n<p>Retatrutide fue dise\u00f1ado para activar GIP, GLP-1 y los receptores de glucag\u00f3n. El art\u00edculo 2023 es el registro central de rango de dosis en humanos, revisado por pares, para el compuesto en la obesidad, por lo que es m\u00e1s \u00fatil que los res\u00famenes que mencionan s\u00f3lo el mayor cambio porcentual sin los grupos de dosis, el resultado del placebo ni las observaciones de seguridad.<\/p>\n<h2>C\u00f3mo se estructur\u00f3 el juicio<\/h2>\n<p>Los adultos que cumpl\u00edan con los criterios BMI y con condiciones relacionadas con el peso fueron asignados al azar a seis reg\u00edmenes de retatrutida y placebo. La proporci\u00f3n de asignaci\u00f3n y los diferentes esquemas de dosis iniciales fueron parte del dise\u00f1o, lo que significa que el estudio evaluaba la respuesta a la dosis y la tolerabilidad, as\u00ed como las se\u00f1ales de eficacia. El criterio de valoraci\u00f3n semana-24 fue el principal; La semana 48 fue secundaria.<\/p>\n<h2>\u00bfQu\u00e9 significan los n\u00fameros?<\/h2>\n<p>El mayor cambio medio informado ocurri\u00f3 en el grupo de mg de 12, pero la publicaci\u00f3n tambi\u00e9n inform\u00f3 una respuesta gradual en los grupos de mg de 1, 4 y 8 y una comparaci\u00f3n con placebo. Los resultados de umbral en la semana 48 tambi\u00e9n variaron seg\u00fan el grupo. Estas son estimaciones de ensayos a nivel de grupo, no un pron\u00f3stico para un individuo y no evidencia de que un producto vendido bajo el mismo nombre compuesto sea intercambiable con la intervenci\u00f3n del estudio.<\/p>\n<div class=\"pfm-case-callout\"><strong>Verificaci\u00f3n de interpretaci\u00f3n:<\/strong> la cifra \u221224.2%, que se repite con frecuencia, es la media de m\u00ednimos cuadrados para un grupo aleatorizado en la semana 48. No es el resultado de todos los participantes y no se gener\u00f3 mediante un ensayo directo de retatrutida versus tirzepatida.<\/div>\n<h2>Lo que queda sin resolver<\/h2>\n<p>El ensayo respalda una se\u00f1al humana de fase 2 y una discusi\u00f3n dosis-respuesta. No establece mantenimiento a largo plazo, eventos adversos raros, efectividad comparativa, equivalencia de fabricaci\u00f3n o aprobaci\u00f3n regulatoria. Esas preguntas requieren ensayos posteriores y datos de productos revisados \u200b\u200bpor los reguladores.<\/p>","protected":false},"excerpt":{"rendered":"<p>Una lectura rastreable de la fuente del ensayo aleatorizado sobre obesidad en fase 2, que incluye los resultados del grupo de dosis, el patr\u00f3n de eventos adversos y los l\u00edmites de la aplicaci\u00f3n de un registro de intervenci\u00f3n cl\u00ednica al material de investigaci\u00f3n.<\/p>","protected":false},"author":0,"featured_media":850,"template":"","class_list":["post-722","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks<\/title>\n<meta name=\"description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\" \/>\n<meta property=\"og:description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"name\":\"Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ensayo Retatrutide fase 2: adultos 338, semanas 48","description":"Una lectura rastreable de la fuente del ensayo aleatorizado sobre obesidad en fase 2, que incluye los resultados del grupo de dosis, el patr\u00f3n de eventos adversos y los l\u00edmites de la aplicaci\u00f3n de un registro de intervenci\u00f3n cl\u00ednica al material de investigaci\u00f3n.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_locale":"es_ES","og_type":"article","og_title":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks","og_description":"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.","og_url":"https:\/\/nhdbio.com\/es\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Tiempo de lectura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","name":"Ensayo Retatrutide fase 2: adultos 338, semanas 48","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Una lectura rastreable de la fuente del ensayo aleatorizado sobre obesidad en fase 2, que incluye los resultados del grupo de dosis, el patr\u00f3n de eventos adversos y los l\u00edmites de la aplicaci\u00f3n de un registro de intervenci\u00f3n cl\u00ednica al material de investigaci\u00f3n.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/722\/revisions"}],"predecessor-version":[{"id":727,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/case_study\/722\/revisions\/727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/850"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}